I am myself a doctor, My Height is 5ft 7in, weight 98kgs , so I am thinking of taking Semaglutide for me Is it wise For me to take ? For weight loss
Reading Document
Medical Text Search
semaglutide weight loss obesity indications eligibility BMI criteria
Medical Text Search
semaglutide contraindications side effects safety profile GLP-1 agonist
Medical Text Search
semaglutide dosing regimen weight management Wegovy Ozempic
GradeResponse
GradeResponse
GradeResponse
Here is a thorough assessment for you:
Your BMI & Eligibility for Semaglutide
First, your numbers:
| Parameter | Value |
|---|---|
| Height | 5 ft 7 in (170.2 cm) |
| Weight | 98 kg |
| BMI | 33.8 kg/m² |
| Classification | Class I Obesity |
Is Semaglutide Appropriate for You?
Yes — you meet the approved criteria.
Semaglutide 2.4 mg SC once weekly (brand: Wegovy) is FDA-approved for chronic weight management in adults with:
- BMI ≥ 30 kg/m² (obesity) — you qualify here directly, OR
- BMI ≥ 25 kg/m² with at least one weight-related comorbidity (hypertension, T2DM, hyperlipidemia)
(Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes, p. 6)
Your BMI of ~33.8 kg/m² places you well within the primary indication threshold.
What to Expect
Efficacy
- The STEP trials demonstrated ~15–17% mean body weight reduction with semaglutide 2.4 mg over 68 weeks when combined with lifestyle intervention.
- For you at 98 kg, that translates to a potential loss of ~15–17 kg (~33–37 lbs), bringing you close to the 80–83 kg range.
- The SELECT Trial also confirmed significant cardiovascular risk reduction with semaglutide in overweight/obese adults without diabetes.
Dosing Schedule (Wegovy — Weight Management)
| Week | Dose |
|---|---|
| 1–4 | 0.25 mg SC once weekly |
| 5–8 | 0.5 mg SC once weekly |
| 9–12 | 1.0 mg SC once weekly |
| 13–16 | 1.7 mg SC once weekly |
| 17+ (maintenance) | 2.4 mg SC once weekly |
Gradual escalation minimizes GI side effects.
Safety Considerations
Common Side Effects
- Nausea, vomiting, diarrhea, constipation — most common, usually transient; mitigated by dose escalation and smaller meal sizes (Cardiovascular Risk Reduction in T2D and ASCVD Guidelines, p. 11)
- Gallbladder disease / acute cholecystitis — increased risk with rapid weight loss + GLP-1 effect; monitor if you develop RUQ pain
Contraindications — Check These Off
| Contraindication | Notes |
|---|---|
| Personal/family history of medullary thyroid carcinoma (MTC) | Absolute contraindication |
| MEN type 2 syndrome | Absolute contraindication |
| Pancreatitis (history of) | Relative — use with caution |
| Pregnancy / planning pregnancy | Avoid |
| Severe gastroparesis or GI motility disorders | Use with caution |
Practical Points (Doctor to Doctor)
- Baseline workup before starting: TSH, LFTs, lipid panel, fasting glucose/HbA1c, renal function, and a gallbladder screen if symptomatic.
- Lifestyle adjunct is essential — trials show best results with concurrent dietary modification and physical activity. Semaglutide is not a standalone fix.
- Distinguish Wegovy vs. Ozempic: Ozempic (max 2 mg) is licensed for T2DM glycemic control; Wegovy (2.4 mg) is the weight-management formulation. Since you don't mention diabetes, Wegovy is the correct indication.
- Weight regain on discontinuation is well-documented (~2/3 of lost weight regained within 1 year of stopping) — set realistic long-term expectations.
- Cardiovascular benefit: Given your BMI and likely cardiovascular risk profile, the SELECT trial data makes semaglutide a particularly compelling choice beyond just aesthetics.
- Monitor: HbA1c (can cause mild hypoglycemia if combined with other agents), heart rate (slight increase seen in trials), and GI symptoms at each dose escalation.
Bottom Line
Given your BMI of ~33.8 kg/m², semaglutide 2.4 mg (Wegovy) is both clinically indicated and evidence-backed for your situation. As a physician, you're well-positioned to self-monitor. The main things to rule out before starting are a personal or family history of MTC/MEN2, and active pancreatitis. Combined with dietary changes, you can realistically expect 12–17% weight reduction over 12–18 months.
Can I Take starting dose 0.5mg ?
Technically yes, but it is not recommended — here's why:
Standard Escalation vs. Skipping the 0.25 mg Start
The 0.25 mg starting dose for weeks 1–4 is not a therapeutic dose — it serves a purely tolerability purpose:
| Dose | Purpose |
|---|---|
| 0.25 mg (weeks 1–4) | GI tolerability priming — NOT for weight loss effect |
| 0.5 mg (weeks 5–8) | First sub-therapeutic step up |
| 1.0 mg → 1.7 mg → 2.4 mg | Progressive therapeutic range |
What Happens if You Start at 0.5 mg?
- GI side effects hit harder — nausea, vomiting, and diarrhea are significantly more likely and more severe without the 0.25 mg ramp-up phase
- The GLP-1 receptor in the gut needs gradual exposure; jumping to 0.5 mg bypasses this adaptation window
- Many patients who skip the ramp-up discontinue early due to intolerable nausea — this is well-documented in real-world data
- No additional weight loss benefit from starting higher — the 2.4 mg maintenance dose is what drives efficacy, not the starting dose
As a Physician, Could You Compress the Schedule?
Some clinicians do a modified escalation if tolerability is good:
| Week | Modified Dose |
|---|---|
| 1–2 | 0.25 mg |
| 3–4 | 0.25 mg (confirm tolerability) |
| 5+ | Escalate per standard schedule |
But compressing below 4 weeks at 0.25 mg is not advised — the prescribing information and STEP trial protocols both use 4-week intervals for a reason.
Bottom Line
Start at 0.25 mg as directed. You gain nothing therapeutically by jumping to 0.5 mg at week 1, and you risk GI side effects severe enough to make you abandon the medication entirely. The 4-week ramp-up is a small patience investment for a much smoother experience through the full 68-week course.
So give me a schedule
Here is your complete Wegovy dosing schedule:
Your Semaglutide (Wegovy) Dosing Schedule
| Phase | Weeks | Dose | Injection Day |
|---|---|---|---|
| Ramp-up 1 | Week 1–4 | 0.25 mg SC once weekly | Pick a fixed day (e.g. Monday) |
| Ramp-up 2 | Week 5–8 | 0.50 mg SC once weekly | Same day weekly |
| Ramp-up 3 | Week 9–12 | 1.0 mg SC once weekly | Same day weekly |
| Ramp-up 4 | Week 13–16 | 1.7 mg SC once weekly | Same day weekly |
| Maintenance | Week 17 onwards | 2.4 mg SC once weekly | Same day weekly |
Injection Sites
Rotate between:
- Abdomen (preferred)
- Anterior thigh
- Upper arm
Avoid injecting in the same spot consecutively.
Key Rules
- Same day every week — consistency matters; if you miss a dose by >5 days, skip it and resume the next scheduled day
- Inject any time of day — with or without food
- If GI side effects are intolerable at any step — stay at the current dose for an extra 4 weeks before stepping up; do not push through severe nausea
- Store in refrigerator (2–8°C); once in use, can be kept at room temperature up to 28 days
What to Monitor at Each Phase
| Timepoint | Check |
|---|---|
| Baseline (before starting) | HbA1c, fasting glucose, LFTs, lipid panel, renal function, HR, BP |
| Week 8 | Tolerability, weight, HR, BP |
| Week 16 | Weight, LFTs, any GI complaints |
| Week 24 | Full metabolic panel, weight, cardiovascular risk reassessment |
| Monthly from Week 17 | Weight trend, HR, BP |
Expected Weight Loss Timeline
| Timepoint | Expected Weight Loss |
|---|---|
| 3 months | ~3–5 kg |
| 6 months | ~7–10 kg |
| 12 months | ~12–15 kg |
| 17–18 months | ~15–17 kg (plateau at maintenance dose) |
At your current weight of 98 kg, target range is approximately 81–83 kg at full therapeutic effect.
Good luck — the most important thing is staying consistent with the weekly injection day and not rushing the escalation.
Tell me Tirzapetide should I take or semaglutide?
Medical Text Search
tirzepatide vs semaglutide weight loss efficacy comparison clinical trials
Medical Text Search
tirzepatide dosing schedule contraindications side effects safety obesity
GradeResponse
GradeResponse
Here is a direct head-to-head comparison to help you decide:
Tirzepatide vs. Semaglutide — Head-to-Head
Mechanism of Action
| Semaglutide | Tirzepatide | |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Targets | 1 receptor | 2 receptors |
| Brand (weight) | Wegovy | Zepbound |
| Brand (diabetes) | Ozempic | Mounjaro |
Tirzepatide's dual mechanism (GLP-1 + GIP) is the key differentiator — GIP agonism enhances insulin secretion, reduces glucagon, and may have additive fat-burning effects on top of GLP-1.
Efficacy — The Numbers That Matter
| Trial | Drug | Weight Loss |
|---|---|---|
| STEP 1 | Semaglutide 2.4 mg + lifestyle | 14.9% from baseline |
| STEP 3 | Semaglutide + intensive lifestyle | 16% from baseline |
| SURMOUNT 1 | Tirzepatide 15 mg + lifestyle | 20.9% from baseline |
| SURMOUNT 3 | Tirzepatide 15 mg + intensive lifestyle | 25% from baseline |
(Nutritional Priorities to Support GLP-1 Therapy for Obesity, p. 13)
For you at 98 kg:
| Drug | Expected Loss | Target Weight |
|---|---|---|
| Semaglutide 2.4 mg | ~15–17 kg | ~81–83 kg |
| Tirzepatide 15 mg | ~20–24 kg | ~74–78 kg |
Tirzepatide wins clearly on efficacy — the 25% reduction from SURMOUNT 3 is the largest weight loss ever recorded in a pharmacological obesity trial.
Dosing Schedule — Tirzepatide (Zepbound)
| Phase | Weeks | Dose |
|---|---|---|
| Ramp-up 1 | Week 1–4 | 2.5 mg SC once weekly |
| Ramp-up 2 | Week 5–8 | 5 mg SC once weekly |
| Ramp-up 3 | Week 9–12 | 7.5 mg SC once weekly |
| Ramp-up 4 | Week 13–16 | 10 mg SC once weekly |
| Ramp-up 5 | Week 17–20 | 12.5 mg SC once weekly |
| Maintenance | Week 21+ | 15 mg SC once weekly |
Side Effects — Nearly Identical
Both share the same GLP-1 class side effect profile:
| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea/vomiting | Common | Common |
| Diarrhea/constipation | Common | Common |
| Gallbladder disease | Yes | Yes |
| Pancreatitis risk | Yes | Yes |
| Heart rate increase | Mild | Mild |
(Obesity Management Algorithm, p. 9)
Tirzepatide may have slightly less nausea in some studies — the GIP component appears to partially offset GLP-1-driven GI effects.
Contraindications — Same for Both
- Personal/family history of medullary thyroid carcinoma
- MEN type 2
- History of pancreatitis (relative)
- Pregnancy
So Which Should YOU Take?
| Factor | Verdict |
|---|---|
| Greater weight loss | ✅ Tirzepatide wins (~20–25% vs ~15–17%) |
| Cardiovascular outcome data | ✅ Semaglutide (SELECT trial — robust CV benefit proven); Tirzepatide CV data still emerging (SURPASS-CVOT ongoing) |
| GI tolerability | Tirzepatide slightly better tolerated |
| Availability & cost | Semaglutide more widely available; tirzepatide newer and may be pricier |
| Longer track record | Semaglutide |
Bottom Line Recommendation
If your primary goal is maximum weight loss → Tirzepatide (Zepbound) 15 mg is the stronger choice. It outperforms semaglutide on every efficacy metric and has a comparable safety profile.
If you have cardiovascular risk factors or prefer a drug with longer real-world data → Semaglutide remains excellent and the SELECT trial gives it a proven CV mortality benefit that tirzepatide hasn't yet fully established in trials.
Given your BMI of 33.8 and no diabetes mentioned, Tirzepatide is arguably the better pick for you — more weight loss, similar safety, and possibly better GI tolerability. The only caveat is ensuring it is available and approved in your country.
Any other precautions or drug should I take along with
Medical Text Search
semaglutide tirzepatide drug interactions precautions monitoring obesity management
Medical Text Search
obesity weight loss adjunct therapy supplements vitamins nutritional deficiency GLP-1
GradeResponse
GradeResponse
Medical Text Search
GLP-1 obesity muscle mass loss protein intake exercise resistance training
Medical Text Search
metformin vitamin B12 deficiency obesity insulin resistance adjunct
Here is a comprehensive breakdown of everything you should take alongside, monitor, and watch out for:
Precautions & Adjunct Recommendations
1. Nutritional Supplements — Critical
GLP-1/GIP agonists cause 16–39% reduction in caloric intake. At intakes below 1800 kcal/day in males, deficiencies develop rapidly. (Nutritional Priorities to Support GLP-1 Therapy for Obesity, p. 5)
Mandatory supplements to take daily:
| Supplement | Dose | Why |
|---|---|---|
| Multivitamin (high potency) | 1 daily | Broad micronutrient cover |
| Vitamin D3 | 1000–2000 IU/day | Deficiency common in obesity; worsens with reduced intake |
| Calcium | 500–1000 mg/day | Reduced dairy intake on low-cal diet |
| Vitamin B12 | 500–1000 mcg/day | GI changes reduce absorption; critical for nerve function |
| Magnesium | 200–400 mg/day | Lost with reduced food intake + GI side effects |
| Iron | Only if labs show deficiency | Monitor; don't supplement blindly |
| Omega-3 (Fish Oil) | 1–2 g/day | Cardiovascular protection, anti-inflammatory |
| Zinc | 8–11 mg/day | Hair loss (common complaint on GLP-1s) prevention |
Watch for: fatigue beyond expected levels, excessive hair loss, muscle weakness, poor wound healing, unusual bruising — these are red flags for frank nutritional deficiency.
2. Protect Muscle Mass — Very Important
A major concern with rapid weight loss on GLP-1/GIP agents is loss of lean muscle mass (up to 25–40% of total weight lost can be muscle, not fat).
What to do:
| Action | Target |
|---|---|
| Protein intake | 1.2–1.6 g/kg/day → for you: ~118–157 g protein/day |
| Resistance training | At least 3x/week — non-negotiable |
| Whey protein supplement | 25–30 g post-workout if dietary protein is insufficient |
| Creatine monohydrate | 3–5 g/day — well-evidenced for preserving muscle during caloric deficit |
3. Drug Interactions — Check These
| Drug/Class | Interaction | Action |
|---|---|---|
| Oral contraceptives / oral medications | GLP-1s slow gastric emptying → reduced absorption of oral drugs | Take oral meds 1 hour before or 4 hours after injection |
| Insulin / Sulfonylureas | Hypoglycemia risk (relevant if you treat yourself for any glucose issue) | Adjust doses if applicable |
| Warfarin | Altered absorption possible | Monitor INR more frequently |
| Levothyroxine | Absorption may be reduced | Take on empty stomach, separate from injection |
| Alcohol | Worsens nausea, risk of pancreatitis | Minimize or avoid |
4. Lifestyle Precautions
| Area | Recommendation |
|---|---|
| Meal size | Small, frequent meals — large meals trigger severe nausea |
| Avoid high-fat meals | Fat slows gastric emptying further — worsens GI symptoms |
| Hydration | 2.5–3 L water/day — especially important with diarrhea/vomiting episodes |
| Alcohol | Minimize — increases pancreatitis risk and worsens GI side effects |
| Smoking | Avoid — compounds cardiovascular risk |
5. Regular Monitoring Schedule
| Test | Frequency |
|---|---|
| Weight + BP + HR | Monthly |
| Fasting glucose + HbA1c | Every 3 months |
| LFTs + Lipid panel | Every 6 months |
| Renal function (eGFR) | Every 6 months |
| Vitamin D, B12, Iron, Magnesium | Every 6 months |
| Thyroid (TSH) | Annually |
| Abdominal exam / amylase/lipase | If any abdominal pain develops — rule out pancreatitis immediately |
6. Red Flag Symptoms — Stop and Investigate
| Symptom | Concern |
|---|---|
| Severe persistent abdominal pain | Pancreatitis — stop drug immediately |
| RUQ pain + nausea | Acute cholecystitis |
| Neck lump / hoarseness | Thyroid concern — MTC screening |
| Severe persistent vomiting | Dehydration + consider dose reduction |
| Excessive fatigue, hair loss, weakness | Nutritional deficiency — check labs |
Summary — Your Adjunct Plan
| Category | Action |
|---|---|
| Supplements | Multivitamin, D3, B12, Calcium, Magnesium, Omega-3, Zinc daily |
| Muscle protection | High protein diet + resistance training 3x/week + consider Creatine |
| Drug timing | Separate oral medications by 1–4 hours from meals |
| Diet | Small meals, low fat, high protein, well hydrated |
| Labs | Every 3–6 months comprehensive panel |
| Alcohol | Minimize or eliminate |
You are in a good position as a physician to self-monitor rigorously — the key risks to stay ahead of are nutritional deficiency, muscle loss, and pancreatitis, all of which are preventable with the above plan.
Any other precautions or drug should I take along with, Ur valuable suggestions
Based on your profile (doctor, BMI 33.8, starting tirzepatide/semaglutide for weight loss), here are my additional suggestions going beyond the standard checklist:
1. Consider Metformin as an Adjunct
Even without frank T2DM, at BMI 33.8 you very likely have insulin resistance.
| Benefit | Detail |
|---|---|
| Improves insulin sensitivity | Addresses the root metabolic driver of your obesity |
| Additive weight loss | Additional ~2–3 kg on top of GLP-1 effect |
| Cardiovascular protection | UKPDS data — proven CV benefit independent of glucose |
| Cheap, safe, well-tolerated | Decades of safety data |
| Reduces T2DM progression | By ~31% in obese pre-diabetic patients (DPP trial) |
Dose: Start 500 mg OD with dinner → titrate to 1000 mg BD over 4 weeks
Precaution: Take Vitamin B12 500–1000 mcg daily — Metformin depletes B12 chronically (check B12 levels every 6 months)
2. Check & Treat Vitamin D Aggressively
Obesity traps Vitamin D in fat tissue — most obese individuals are frankly deficient, not just insufficient.
| Action | Detail |
|---|---|
| Check 25-OH Vitamin D level first | Target: >50 ng/mL (not just >30) |
| If deficient (<20 ng/mL) | Load with 60,000 IU/week for 8 weeks, then 2000 IU/day maintenance |
| If insufficient (20–30 ng/mL) | 2000–4000 IU/day directly |
Low Vitamin D independently worsens insulin resistance, causes fatigue, muscle weakness, and depression — all of which undermine your weight loss effort.
3. Get a Full Metabolic Workup Before Starting
As a doctor you know this, but do it for yourself — we tend to neglect our own workups:
| Test | Why |
|---|---|
| Fasting insulin + HOMA-IR | Quantify insulin resistance objectively |
| HbA1c | Rule out undiagnosed pre-diabetes/T2DM |
| Thyroid panel (TSH, FT3, FT4) | Hypothyroidism is a reversible cause of weight gain — exclude before attributing everything to lifestyle |
| Testosterone (Total + Free) | Obesity causes hypogonadism in males → low T worsens fat accumulation and muscle loss — a treatable cycle |
| Cortisol (morning) | Rule out subclinical Cushing's if weight is predominantly truncal |
| Liver USG + LFTs | At BMI 33.8, MASLD (metabolic fatty liver) is highly prevalent — tirzepatide actually helps this too |
| Sleep study or STOP-BANG score | Obstructive sleep apnoea is very common at your BMI and worsens metabolic syndrome |
| Lipid panel (full) | LDL, HDL, TG, non-HDL, LDL particle size if available |
| hsCRP | Marker of systemic inflammation — elevated in obesity, tracks improvement |
| Uric acid | Rapid weight loss can precipitate gout — baseline important |
4. Uric Acid — Often Overlooked
Rapid weight loss from GLP-1/GIP agents can trigger acute gout due to sudden uric acid flux.
- Check baseline uric acid
- If elevated (>7 mg/dL): consider Febuxostat 40 mg/day prophylactically
- Stay well hydrated (3L/day) — this alone reduces risk significantly
5. Address Sleep — Non-Negotiable
| Issue | Impact |
|---|---|
| Poor sleep (<6 hrs) | Raises ghrelin, lowers leptin — directly counteracts GLP-1 appetite suppression |
| Obstructive sleep apnoea | Worsens insulin resistance, hypertension, cardiovascular risk |
| Sleep deprivation | Increases cortisol → promotes visceral fat retention |
Action: Do a STOP-BANG questionnaire on yourself. If high risk, get a polysomnography done. Treating OSA alone can improve metabolic parameters significantly.
6. Gut Health — Underrated
GLP-1 receptors are heavily expressed in the gut. A dysbiotic gut microbiome blunts GLP-1 response.
| Action | Detail |
|---|---|
| Probiotic | Lactobacillus + Bifidobacterium blend daily — improves gut motility and reduces GI side effects of the drug |
| Prebiotic fiber | 25–35 g/day dietary fiber — feeds beneficial gut bacteria |
| Avoid NSAIDs | Damage gut lining, worsen GI side effects of tirzepatide/semaglutide |
7. Psychological & Behavioral Support
This is the most underused tool in obesity management by physician-patients:
| Action | Why |
|---|---|
| Identify your eating triggers | Emotional eating, stress eating, night eating — drug won't fix behavioral patterns |
| Structured meal timing | 3 meals, no snacking — aligns with slowed gastric emptying |
| Keep a food + weight diary | Accountability — even for 12 weeks at the start |
| Avoid "eating back" exercise calories | Common mistake that blunts drug efficacy |
8. Alcohol — Be Honest With Yourself
| Risk | Detail |
|---|---|
| Pancreatitis | Alcohol + GLP-1 agent = significantly elevated risk |
| Empty calories | Directly undermines caloric deficit |
| Hepatotoxicity | Especially if MASLD already present |
| Hypoglycemia | If combining with metformin |
Recommendation: Complete abstinence during the active weight loss phase (first 6–12 months) is ideal. If not feasible, strictly limit to 1 unit/week.
9. Your Full Suggested Regimen Summary
| Category | Drug/Action | Dose |
|---|---|---|
| Primary | Tirzepatide (Zepbound) | 2.5 mg → titrate to 15 mg weekly |
| Adjunct metabolic | Metformin (if HOMA-IR elevated) | 500 mg OD → 1000 mg BD |
| Vitamin D | D3 (after checking levels) | 2000–4000 IU/day |
| B12 | Methylcobalamin | 1000 mcg/day |
| Magnesium | Magnesium glycinate | 300–400 mg/day (better absorbed, less GI upset) |
| Omega-3 | Fish oil | 2 g/day |
| Zinc | Zinc picolinate | 15–25 mg/day |
| Creatine | Creatine monohydrate | 5 g/day |
| Probiotic | Multi-strain | 10–20 billion CFU/day |
| Exercise | Resistance training | 3–4x/week mandatory |
| Protein | Dietary + whey if needed | 1.2–1.6 g/kg/day (~118–157 g/day) |
| Sleep | Target 7–8 hrs, rule out OSA | STOP-BANG + polysomnography if needed |
| Uric acid | Check baseline; Febuxostat if >7 mg/dL | 40 mg/day if needed |
One Final Honest Note
You are a doctor — you know all of this intellectually. The hard part is compliance with your own plan. The most common failure mode for physician-patients is:
- Skipping labs ("I'll do it next month")
- Skipping resistance training ("too busy")
- Underestimating alcohol intake
- Not addressing sleep
The drug will do its job. Your job is everything around it. That combination is what gets you from 98 kg to 78 kg — and keeps you there.
This is a shared conversation. Sign in to Orris to start your own chat.